The French laboratory is lending a hand. Sanofi will help Pfizer and BioNTech to produce their vaccine against Covid-19 and should package more than 100 million doses intended for the European Union by the end of 2021, Paul Hudson, the director general of the French laboratory, announced on Tuesday in an interview with Figaro.
Sanofi is working on two vaccines itself to fight this pandemic, but its main project is behind schedule and is not expected to hit the market before the end of the year. In the meantime, the French government had urged it on several occasions in recent weeks to study the possibility of making its production lines available to increase the production of already existing vaccines.
Announcing to have signed an agreement on Tuesday, Paul Hudson explains in the interview published on the website of the Figaro that Sanofi will use its German factory in Frankfurt to bottle the vaccine that will be supplied to it by its competitors from July.
Limited offer. 2 months for 1 € without commitment
“This production site is located near the headquarters of BioNTech [à Mayence]This will make things easier, “argues the boss of the French group. The production will be intended for the European Union and therefore in part to France, he added.
Laboratories have to cope with high speeds to meet demand and some, including Pfizer and BioNTech, have had to face delays.
Pressure from europe
On Tuesday, the President of the European Commission, Ursula von der Leyen, put further pressure on manufacturers by saying that they had to “honor their obligations”. “Europe has invested billions to develop the first vaccines and create a real global common good. Now companies must keep their promises,” she argued in a video intervention at the World Economic Forum in Davos.
Regarding his own projects, Paul Hudson ensures that the recombinant protein one, a technology that Sanofi uses for its influenza vaccine, “is progressing well”, despite a few months of delay, and should arrive on the market in the last quarter of 2021.
The laboratory is also developing a vaccine based on messenger RNA technology, used in particular by Pfizer and BioNTech, in partnership with an American biotech. “We think we can enter the clinical phase with an RNA vaccine against Covid from the first quarter of this year,” Paul Hudson hoped.
Lthe keys to power